reviewed april 2026|next review october 2026|88 physicians psi has verified|404733 published studies
NMN (Nicotinamide Mononucleotide)
Nicotinamide mononucleotide (NMN) is a nucleotide (not a peptide) that serves as a direct precursor to NAD+ (nicotinamide adenine dinucleotide), a coenzyme essential for cellular energy production, DNA repair, and sirtuin activation that declines with age, included in PSI's compound library due to its prominence in peptide-adjacent longevity research and the biohacking community.
Evidence landscape: 404733 published studies
Published studies indexed under this compound. NMN has more peer-reviewed human trial data than most compounds in the longevity space, though the total remains small relative to the marketing presence.
- 9 Human
- 156 Animal
- 35 Reviews
- 404533 Other research
Not FDA-approved as a drug. Sold as a dietary supplement in the United States. FDA issued a warning letter in 2022 classifying NMN as a drug candidate, temporarily restricting supplement sales. This was challenged and NMN remains commercially available as a supplement.
Widely available as a dietary supplement from multiple manufacturers. This is one of the most commercially available compounds on PSI's platform. Multiple human clinical trials have been completed using commercially sourced NMN.
NMN is technically a nucleotide, not a peptide. It is included in PSI's compound library because of its significant overlap with peptide longevity research (sirtuin activation, NAD+ biology) and its prominence in the communities that use PSI. NMN is one enzymatic step from NAD+ (converted by NMNAT enzymes). The competing precursor NR (nicotinamide riboside, sold as Niagen) is two enzymatic steps from NAD+.
PSI Assessment
NAD+ is required for hundreds of metabolic reactions in every cell. It powers mitochondrial energy production, activates sirtuin longevity genes, and enables DNA repair. NAD+ levels decline with age, and restoring them is one of the most active hypotheses in longevity research. NMN is the most direct precursor to NAD+ (one enzymatic step away), and multiple human clinical trials now show that oral NMN supplementation reliably raises blood NAD+ levels. The central question is not whether NMN raises NAD+. That is established. The question is whether raising NAD+ produces meaningful health benefits in humans.
Reliable NAD+ elevation in human trials. The biology is real. Whether that elevation translates to clinical longevity or disease-prevention benefits in humans is the central unanswered question.
The mechanism is NAD+ precursor biochemistry. NMN is converted to NAD+ by NMNAT (nicotinamide mononucleotide adenylyltransferase) enzymes. Elevated NAD+ activates sirtuins (SIRT1-7, deacetylase enzymes that regulate gene expression, DNA repair, and mitochondrial function), supports PARP-mediated DNA repair, and maintains mitochondrial electron transport chain function. NMN enters cells via the Slc12a8 transporter. The competing precursor NR (nicotinamide riboside) uses a different cellular entry pathway and requires an additional enzymatic step (NRK-mediated phosphorylation) to reach NMN before conversion to NAD+.
What the evidence supports
Oral NMN reliably raises blood and tissue NAD+ levels in human clinical trials. This is reproducible across multiple studies. NAD+ decline with aging is well-established biology. NMN improved muscle insulin sensitivity in postmenopausal women with prediabetes (Yoshino et al., 2021, Science). NMN improved aerobic capacity in recreational runners. Long-term NMN administration reversed age-related metabolic decline in mice.
What is not yet established
Whether the documented NAD+ elevation translates to meaningful clinical longevity or disease-prevention benefits in humans. NMN versus NR (nicotinamide riboside) superiority for any clinical outcome. Optimal dosing for human health outcomes. Long-term safety of chronic NAD+ elevation. Whether supplemental NMN provides benefits beyond what exercise and caloric balance achieve.
Research Evidence
The findings below cover the animal data that launched the field, the human clinical trials confirming NAD+ elevation, and the emerging evidence for metabolic benefits.
Evidence by condition
Evidence dimensions across NMN research areas. NAD+ restoration has the deepest human evidence. Metabolic benefits have one strong trial (Yoshino, Science 2021). Longevity and cognitive applications remain primarily in animal models (animal research).
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| NAD+ Restoration | ||||
| Longevity | ||||
| Metabolic Health | ||||
| Cognitive Function |
Long-term NMN administration in mice reversed age-related metabolic decline, improving insulin sensitivity, lipid metabolism, physical activity, and energy metabolism. Treated mice showed physiological profiles more similar to younger animals.
This foundational animal study established NMN as a leading NAD+ precursor intervention. The mouse data is compelling but the dose-to-human translation is not straightforward. Mouse studies used doses equivalent to roughly 1-2 grams per day in humans, far above typical supplement doses.
A randomized, double-blind, placebo-controlled trial in postmenopausal women with prediabetes showed that 10 weeks of NMN supplementation (250 mg/day) improved skeletal muscle insulin sensitivity by approximately 25% as measured by hyperinsulinemic-euglycemic clamp (the gold-standard technique).
This Yoshino et al. (2021) Science paper provided the first rigorous human evidence for a metabolic benefit of NMN. The sample size was small (25 participants) and the study population was specific (postmenopausal women with prediabetes), limiting generalizability.
A multicenter randomized trial testing 300 mg and 600 mg daily NMN in healthy middle-aged adults for 60 days showed significant NAD+ elevation at both doses. Walking endurance improved and no serious adverse events occurred.
This trial confirmed that NMN reliably raises NAD+ in healthy humans and established short-term safety at typical supplement doses. The functional outcomes (walking endurance) are modest compared to the marketing claims that surround NMN supplementation.
9 Human|156 Animal|35 Reviews
View all 404733 indexed studiesHow NMN (Nicotinamide Mononucleotide) Works
NAD+ is like a rechargeable battery that every cell needs. It powers energy production, DNA repair, and sirtuin longevity genes. NAD+ levels drop with age. NMN is one enzymatic step from NAD+, and the body converts NMN to NAD+, potentially recharging cellular batteries. The question is whether recharging the batteries at the molecular level produces benefits people can feel.
NAD+ is like a rechargeable battery that every cell needs. It powers energy production, DNA repair, and sirtuin longevity genes. Levels drop with age. NMN is one enzymatic step from NAD+, and the body converts NMN to NAD+, potentially recharging cellular batteries.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
NMN (C11H15N2O8P) is a nucleotide intermediate in the NAD+ salvage pathway. It is phosphorylated by NRK (nicotinamide riboside kinase) from NR, or synthesized from nicotinamide by NAMPT (the rate-limiting enzyme). NMN is then adenylylated by NMNAT1-3 (nicotinamide mononucleotide adenylyltransferase) to produce NAD+. Elevated NAD+ activates SIRT1-7 (NAD+-dependent protein deacetylases), PARP (poly-ADP-ribose polymerase) 1/2 enzymes for DNA repair, and CD38 (NAD+ glycohydrolase). NMN enters cells via the Slc12a8 transporter in the small intestine. Oral bioavailability has been confirmed in human pharmacokinetic studies.
What is NMN (Nicotinamide Mononucleotide) being studied for?
Researchers are studying NMN (Nicotinamide Mononucleotide) across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for NMN (Nicotinamide Mononucleotide) overall. This means a compound can have human studies for one condition but only animal data for another.
NAD+ Restoration
·Human TrialsOral NMN reliably raises blood and tissue NAD+ levels in human clinical trials. This is reproducible across multiple studies at doses of 250-600 mg/day. NAD+ decline with aging is well-established biology.
Limitations: Whether raising NAD+ produces meaningful health outcomes is the central unanswered question. NAD+ elevation is a biomarker change, not a clinical outcome. The gap between biomarker improvement and health benefit has not been fully bridged.
Longevity
·Animal StudiesNMN reverses age-related metabolic decline in mice and activates sirtuin longevity pathways. The NAD+/sirtuin axis is one of the most studied longevity mechanisms across species.
Limitations: No human longevity data. Mouse dose-to-human translation is uncertain. Whether supplemental NMN produces benefits beyond what exercise and caloric balance achieve is not established.
Metabolic Health
·Animal StudiesOne rigorous human trial showed NMN improved muscle insulin sensitivity in prediabetic women. Another showed improved walking endurance in healthy middle-aged adults.
Limitations: Human metabolic benefit data comes from small trials with specific populations. Whether these results generalize to the broad consumer base taking NMN supplements is not established.
Cognitive Function
·PreclinicalNAD+ supports neuronal function and mitochondrial health in the brain. NMN improved cognitive parameters in aged mice. No human cognitive trials have been published.
Limitations: Cognitive applications are entirely in animal models (animal research). Whether NMN supplementation affects human cognitive function or age-related cognitive decline is untested.
Safety and Regulatory Status
FDA Status: Not FDA-approved as a drug. Sold as a dietary supplement. FDA issued a 2022 warning letter classifying NMN as a drug candidate. NMN remains commercially available as a supplement in the United States.
Availability: Widely available as a dietary supplement from multiple manufacturers at doses of 250-1000 mg. One of the most commercially accessible compounds on PSI's platform.
Class context: Generally well tolerated in published human studies with no serious adverse events reported. Theoretical concern exists about NAD+ boosting in cancer cells (NAD+ supports rapid cell proliferation). Long-term safety data beyond 12 weeks is limited.
NMN has been well tolerated in published human clinical trials at doses up to 600 mg/day for up to 12 weeks. No serious adverse events have been reported. The theoretical concern about NAD+ boosting in cancer cells (since NAD+ supports rapid cell proliferation) has not been observed clinically but is noted in the literature. Long-term safety data beyond 12 weeks is limited.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a NMN (Nicotinamide Mononucleotide) discussion.
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Foundational study demonstrating that long-term NMN supplementation in mice suppressed multiple hallmarks of aging. Treated mice showed improved insulin sensitivity, better lipid metabolism, enhanced physical activity, and preserved vision. The benefits were dose-dependent and the paper established NMN as a leading NAD+ precursor for age-related metabolic decline research.Mills KF et al., 2016 in Cell Metab. View on PubMed
- 2.Randomized, double-blind, placebo-controlled clinical trial in postmenopausal women with prediabetes. Ten weeks of oral NMN supplementation (250 mg/day) increased skeletal muscle insulin sensitivity and improved insulin signaling pathways. This was one of the first rigorous human trials to demonstrate a metabolic benefit of NMN supplementation.Yoshino M et al., 2021 in Science. View on PubMed
- 3.Multicenter randomized trial testing two doses of NMN (300 mg and 600 mg daily) against placebo in healthy adults for 60 days. Both doses raised blood NAD+ levels significantly. Participants reported improved walking endurance and the supplement was well tolerated with no serious adverse events at either dose level.Yi L et al., 2023 in J Nutr Biochem. View on PubMed
- 4.Randomized, double-blind, placebo-controlled trial in healthy older men (65+) taking 250 mg NMN daily for 12 weeks. NMN supplementation significantly increased whole-blood NAD+ and its metabolites. Gait speed and grip strength showed trends toward improvement, and no adverse effects were observed.Igarashi M et al., 2022 in NPJ Aging. View on PubMed
- 5.Randomized, double-blind study in recreational runners who supplemented with NMN for six weeks during training. The NMN group showed improved aerobic capacity measured by ventilatory threshold compared to placebo. This provided evidence that NMN supplementation may enhance exercise performance through improved skeletal muscle oxygen utilization.Liao B et al., 2021 in J Int Soc Sports Nutr. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.